Asma Dilawari

7PUBLICATIONS
46CO-AUTHORS
Food properties (incl. characteristics and health benefits)Cancer therapy (excl. chemotherapy and radiation therapy)Flight dynamicsMolecular targetsPalliative care
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 05, 2025
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer.

Asma Dilawari, Hui Zhang, Mirat Shah

|Aug 19, 2024
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations.

Asma Dilawari, James Buturla, Christy Osgood

|May 22, 2023
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.

Asma Dilawari, Mirat Shah, Gwynn Ison

|Feb 13, 2023
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.

Preeti Narayan, Asma Dilawari, Christy Osgood

|Dec 02, 2022
Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development.

Elizabeth S Duke, Michael J Fusco, Patrick DeMoss

|Oct 24, 2022
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.

Paula R Pohlmann, Deena Graham, Tianmin Wu

Pageof 2

Frequent Collaborators

5 joint publications

Richard Pazdur

4 joint publications

Laleh Amiri-Kordestani

4 joint publications

Bronwyn Mixter

3 joint publications

William Pierce